GloPID-R report on chikungunya, o’nyong-nyong and Mayaro virus, part 2: Epidemiological distribution of o’nyong-nyong virus


To cite this version:

pasteur-02305872
GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2: Epidemiological distribution of o'nyong-nyong virus

L. Pezzi\textsuperscript{b, c}, A.D. LaBeaud\textsuperscript{c}, C.B. Reusken\textsuperscript{d, e}, J.F. Drexler\textsuperscript{f, g}, N. Vasilakis\textsuperscript{h}, M. Diallo\textsuperscript{i}, F. Simon\textsuperscript{i}, T. Jaenisch\textsuperscript{k}, P. Gallian\textsuperscript{l}, A. Sall\textsuperscript{i}, A.B. Failloux\textsuperscript{m}, S.C. Weaver\textsuperscript{n}, X. de Lamballerie\textsuperscript{a}, on behalf of GloPID-R chikungunya, o'nyong-nyong and Mayaro virus Working Group (S. Boyero\textsuperscript{o}, P. Brasil\textsuperscript{p}, M. Busch\textsuperscript{i}, M.S. Diamond\textsuperscript{q, r}, M.A. Drebot\textsuperscript{u}, A. Kohl\textsuperscript{v}, M. Lecuit\textsuperscript{w}, R. Lourenço-de-Oliveira\textsuperscript{x}, J. Neyts\textsuperscript{y}, Ng Lf\textsuperscript{z}, G.S. Ribeiro\textsuperscript{aa}, M. Rios\textsuperscript{ab}, A.J. Rodriguez-Morales\textsuperscript{ac}, M.G. Rosa-Freitas\textsuperscript{ab}, G. Simmons\textsuperscript{ad}, A.M. Siqueira\textsuperscript{ab}, A. Vega Rua\textsuperscript{ae})

\textsuperscript{a} Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France
\textsuperscript{b} EA7310, Laboratoire de Virologie, Université de Corse-Inserm, Corte, France
\textsuperscript{c} Department of Pediatrics, Division of Infectious Diseases, Stanford University School of Medicine, Stanford, USA
\textsuperscript{d} Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands
\textsuperscript{e} Department Pathology, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, USA
\textsuperscript{f} German Centre for Infection Research (DZIF), Germany
\textsuperscript{g} Department of Pathology, Institute of Human Infection and Immunity, University of Texas Medical Branch, Galveston, USA
\textsuperscript{h} Unité D'Entomologie Médicale, Institut Pasteur de Dakar, Dakar, Senegal
\textsuperscript{i} Laveran Military Teaching Hospital, Marseille, France
\textsuperscript{j} Section Clinical Tropical Medicine, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany
\textsuperscript{k} 1117 Unité des arbovirus, Centre de contrôle des maladies infectieuses et tropicales, Marseille, France
\textsuperscript{l} Department of Virology, Institut Pasteur, Arbovirus and Insect Vectors Unit, Paris, France
\textsuperscript{m} Institute for Human Infections and Immunity and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA
\textsuperscript{n} Medical Entomology Platform, Institut Pasteur Du Camodge, Phnom Penh, Cambodia
\textsuperscript{o} Instituto Nacional de Infectologia Evandro Chagas - Oswaldo Cruz Foundation, Rio de Janeiro, Brazil
\textsuperscript{p} Blood Systems Research Institute, San Francisco, and Department of Laboratory Medicine, University of California, San Francisco, USA
\textsuperscript{q} Department of Medicine, and the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, USA
\textsuperscript{r} Department of Molecular Microbiology, And the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, USA
\textsuperscript{s} Department of Pathology and Immunology, And the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, USA
\textsuperscript{t} Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
\textsuperscript{u} MRC-University of Glasgow Centre for Virus Research, Glasgow, UK
\textsuperscript{v} KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Immunology, Leuven, Belgium
\textsuperscript{w} Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore
\textsuperscript{x} Goncalo Moris Institute, Oswaldo Cruz Foundation, And Federal University of Bahia, Salvador, Brazil
\textsuperscript{y} Instituto Oswaldo Cruz-Fiocruz, Laboratório de Mosquitos Transmissores de Hematozoiros, Rio de Janeiro, Brazil
\textsuperscript{z} Instituto Oswaldo Cruz-Fiocruz, Laboratório de Mosquitos Transmissores de Hematozoiros, Rio de Janeiro, Brazil
\textsuperscript{aa} Goncalo Moris Institute, Oswaldo Cruz Foundation, And Federal University of Bahia, Salvador, Brazil
\textsuperscript{ab} Division of Emerging and Transfusion Transmitted Diseases, Laboratory of Emerging Pathogens, Office of Blood Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA
\textsuperscript{ac} Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Colombia

\textsuperscript{*} Corresponding author. Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille. France.
E-mail address: laura.pezzi3@studio.unibo.it (L. Pezzi).

https://doi.org/10.1016/j.antiviral.2019.104611

Available online 20 September 2019
0166-3542/ © 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness) chikungunya (CHIKV), o’nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group has been established to identify gaps of knowledge about the natural history, epidemiology and medical management of infection by these viruses, and to provide adapted recommendations for future investigations. Here, we present a report dedicated to ONNV epidemiological distribution. Two large-scale ONNV outbreaks have been identified in Africa in the last 60 years, interspersed with sporadic serosurveys and case reports of returning travelers. The assessment of the real scale of ONNV circulation in Africa remains a difficult task and surveillance studies are necessary to fill this gap. The identification of ONNV etiology is made complicated by the absence of multiplex tools in co-circulation areas and that of reference standards, as well as the high cross-reactivity with related pathogens observed in serological tests, in particular with CHIKV. This is a specific obstacle for seroprevalence studies, that necessitate an improvement of serological tools to provide robust results. The scarcity of existing genetic data currently limits molecular epidemiology studies. ONNV epidemiology would also benefit from reinforced entomological and environmental surveillance. Finally, the natural history of the disease deserves to be further investigated, with a specific attention paid to long-term complications. Considering our incomplete knowledge on ONNV distribution, GloPID-R CHIKV, ONNV and MAYV experts recommend that a major effort should be done to fill existing gaps.

1. Introduction

O’nyong-nyong virus (ONNV) is a mosquito-borne alphavirus (family Togaviridae), primarily transmitted through the bite of Anopheles funestus and A. gambiae mosquitoes. After its first isolation from Gulu, Uganda in 1959, ONNV was detected several times in humans and mosquitoes (Rezza et al., 2017); so far, its known geographical distribution is confined to the African continent. It is highly probable that ONNV has been misdiagnosed and/or underreported, because of the circulation in Africa of pathogens causing similar illnesses (i.e., Plasmodium falciparum, chikungunya virus (CHIKV), dengue virus (DENV), and other arboviruses) and of the difficult interpretation of serological results (due to cross-reactivity between antibodies against ONNV and those against CHIKV) (Pezzi et al., 2019).

2. GloPID-R chikungunya (CHIKV), o’nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group

The GloPID-R (Global Research Collaboration for Infectious Disease Preparedness, https://www.glopid-r.org/) chikungunya (CHIKV), o’nyong-nyong (ONNV) and Mayaro virus (MAYV) Working Group has been established to investigate the natural history, epidemiology and clinical aspects of these viruses; the objective was to identify knowledge gaps and to propose recommendations for direct future investigations and rectification measures. After the first report dedicated to diagnostic aspects of CHIKV, ONNV and MAYV (Pezzi et al., 2019), here we present an assessment of the available information regarding the epidemiological distribution of ONNV. It will be followed by a report on CHIKV and MAYV distribution.

3. Sources of data

Data from the first viral isolation until December 2018 were collected, including both acute cases in humans (confirmed by PCR + and/or presence of IgG) as well as results of serological studies showing past infections in humans (presence of IgG). Data were obtained from health organizations and from the peer-reviewed literature concerning African countries. We consulted different public health alert systems websites, including:

- World Health Organization (WHO, 2019) - ‘Disease outbreak news (DON)’ section
- Program for Monitoring Emerging Diseases (ProMED);
- European Centre for Disease Prevention and Control (ECDC) through ‘Communicable disease threats report (CDTR)’;
- Institute of health of each African country, through periodic bulletins on viral infections (when available).

In addition, a comprehensive review of literature using PubMed was conducted with the search terms ‘O’nyong-nyong’ and the name of each African country. Finally, viral sequences available in GenBank were checked, in order to assess the countries where ONNV-positive human samples have been collected.

In the article and in Tables 1–2 of Supplementary data we reported details about ONNV detection: number of cases, year, localization and techniques used to confirm the infection. We classified the sources of our data in 5 categories:

- Declared outbreaks
- Single case reports (mainly about returning travelers)
- Surveillance studies, aiming to identify the etiology of acute illnesses confirmed by PCR and/or serology
- Serosurveys (to evaluate previous exposition to the virus, confirmed by serological tools)
- GenBank sequences, present on the database without additional information on the isolated strains

In this report, experts provided a picture of ONNV geographic distribution through Africa over the last 60 years; in addition, they identified gaps of knowledge and made recommendations in order to suggest research priorities in the field.

4. ONNV distribution

An account of the epidemiological findings about ONNV human cases is shown below. Further details are presented in Table 1 (West Africa) and Table 2 (Central and East Africa) of Supplementary data.

4.1. West Africa

4.1.1. Côte d’Ivoire

1) Outbreak

First reported epidemic caused by Igbo-Ora virus (later determined to be a strain of ONNV). Cases were confirmed in Central Côte d’Ivoire in 1984–1985 by serological tests or by virus isolation. Entomological investigation allowed to detect the virus in A. funestus and A. gambiae (Lhuillier et al., 1988).

...
2) Outbreak

ONNV outbreak was declared in the Nicla Border Camp in western Côte d’Ivoire, among Liberian refugees (Posey et al., 2005). Cases were confirmed positive by serological tests or PCR.

4.1.2. Ghana

1) Serosurvey

A seroprevalence study was performed in travelers returning from tropical Africa in 1975–1977 (Woodruff et al., 1978). Sera from patients with evidence of past infections were tested by haemagglutination inhibition (HI), complement fixation (CF), and indirect immunofluorescence (IF) tests.

4.1.3. Nigeria

1) Case report

Two Igbo-Ora virus strains were isolated from two febrile children in Oyo State, south-western Nigeria, in 1966 (Moore et al., 1975).

2) Case report

An Igbo-Ora virus strain was isolated from an adult patient living in Oyo State, southwestern Nigeria, in 1969 (Moore et al., 1975).

3) Surveillance study

The seroprevalence study was performed in travellers returning from tropical Africa (Woodruff et al., 1978) in 1975–1977. Sera from patients with evidence of past infections were tested by haemagglutination inhibition (HI), complement fixation (CF), and indirect immunofluorescence (IF) tests. One ONNV infection dated back to June 1974, another one to December 1975. A third patient was infected in Nigeria or in Sierra Leone, with no information about the year.

4) Serosurvey

Serosurveillance study performed among voluntary donors in Oyo State, southwestern Nigeria (Olaleye et al., 1988). Sera were tested by HI. Cross-reactivity with antibodies against CHIKV was observed.

4.1.4. Senegal

1) Outbreak

A ONNV outbreak involving both eastern and western Africa (Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon, Central African Republic, Democratic Republic of the Congo) in 1959–1962 accounted for more than 2 million cases in eastern Africa alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was identified as the main vector (Corbet et al., 1961; Williams et al., 1965). The first ONNV strain was isolated from Gulu (Uganda) in 1959.

2) GenBank sequence (no additional information)

An Igbo-Ora strain of ONNV was isolated from human blood sample in 1985. GenBank accession number available in Table 2-Supplementary data.

4.2. Central and East Africa

4.2.1. Cameroon

1) Outbreak

A ONNV outbreak involving both eastern and western Africa (Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon, Central African Republic, Democratic Republic of the Congo) in 1959–1962 accounted for more than 2 million cases in eastern Africa alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was identified as the main vector (Corbet et al., 1961; Williams et al., 1965). The first ONNV strain was isolated from Gulu (Uganda) in 1959.

2) Serosurvey

A seroprevalence study performed in 2000–2003 involved adults in nine rural villages in Cameroon. Sera were tested for ONNV by PRNT (plaque-reduction neutralization test). Cross-reactivity with antibodies against CHIKV was observed (Kuniholm et al., 2006).

3) Surveillance study

A study was conducted in 2004–2005 in the Fako Division (south-west Cameroon). Sera were collected from febrile patients and tested by haemagglutination inhibition (HI) and complement fixation (CF) tests, with 34.2% and 33.3% of positive results, respectively. Cross-reactivity with antibodies against CHIKV was observed (Fokam et al., 2010).

4.2.2. Central African Republic

1) Outbreak

A ONNV outbreak involving both eastern and western Africa (Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon, Central African Republic, Democratic Republic of the Congo) in 1959–1962 accounted for more than 2 million cases in eastern Africa alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was identified as the main vector (Corbet et al., 1961; Williams et al., 1965). The first ONNV strain was isolated from Gulu (Uganda) in 1959.

2) Case report

Imported case - France ex Chad (southern part of the country) (Bessaud et al., 2006). Sera was IgM+ and IgG + anti-ONNV by ELISA; virus was isolated from peripheral blood mononuclear cells.

4.2.3. Chad

1) Case report

Imported case - France ex Chad (southern part of the country) (Bessaud et al., 2006). Sera was IgM+ and IgG + anti-ONNV by ELISA; virus was isolated from peripheral blood mononuclear cells.

4.2.4. Democratic Republic of the Congo

1) Outbreak

A ONNV outbreak involving both eastern and western Africa (Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon, Central African Republic, Democratic Republic of the Congo) in 1959–1962 accounted for more than 2 million cases in eastern Africa alone (Rezza et al., 2017; Haddow et al., 1960). A. funestus was identified as the main vector (Corbet et al., 1961; Williams et al., 1965). The first ONNV strain was isolated from Gulu (Uganda) in 1959.
alone (Rezza et al., 2017; Haddow et al., 1960). *A. funestus* was identified as the main vector (Corbet et al., 1961; Williams et al., 1965). The first ONNV strain was isolated from Gulu (Uganda) in 1959.

2) Serosurvey

Seroprevalence study was conducted in two sites in Western Kenya in 1973: Kalo Plain (67.3% of positivity rate for ONNV) and Bunyala (72.3%) (Marshall et al., 1982). Tests on sera were performed with HI.

3) Outbreak

A ONNV outbreak was first detected in south-central Uganda and then spread to Kenya and Tanzania in 1996–1997 (Sanders et al., 1999). A case-finding serosurvey conducted in January and February 1997 in affected sites in Uganda estimated infection rates at 45–68%. Cross-reactivity with antibodies against CHIKV was observed.

4) Outbreak

ONNV cases were confirmed in Mombasa and Malindi districts (eastern Kenya) in 2004 (ProMED, 20041216.3325).

5) Serosurvey

Seroprevalence study was performed on sera collected in Kwale County, eastern Kenya, in 2009 [16]. Sera were tested with IgG ELISA and PRNT (plaque reduction neutralization test). Cross-reactivity with antibodies against CHIKV was observed, with 168 additional sera with high titres for both viruses with PRNT.

---

**Fig. 1.** Acute ONNV cases in humans confirmed by PCR or virus isolation. Countries (in green) where ONNV infections have been confirmed by HI, VNT, PRNT, IF or ELISA are not classified in the map since massive cross-reactivity with related alphaviruses affects serological assays.
6) Case report

Imported case − Germany ex Kenya in 2013 (Tappe et al., 2014). After a travel in eastern Africa, paired sera were tested by immunofluorescence (IF) and virus neutralization (VNT) tests.

4.2.6. Malawi

1) Outbreak

A ONNV outbreak involving both eastern and western Africa (Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon, Central African Republic, Democratic Republic of the Congo) in 1959–1962 accounted for more than 2 million cases in eastern Africa alone (Rezza et al., 2017; Haddow et al., 1960). *A. funestus* was identified as the main vector (Corbet et al., 1961; Williams et al., 1965). The first ONNV strain was isolated from Gulu (Uganda) in 1959.

4.2.7. Mozambique

1) Outbreak

A ONNV outbreak involving both eastern and western Africa (Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon, Central African Republic, Democratic Republic of the Congo) in 1959–1962 accounted for more than 2 million cases in eastern Africa alone (Rezza et al., 2017; Haddow et al., 1960). *A. funestus* was identified as the main vector (Corbet et al., 1961; Williams et al., 1965). The first ONNV strain was isolated from Gulu (Uganda) in 1959.

4.2.8. South Sudan

1) Outbreak

During an outbreak of haemorrhagic fever syndrome in 2015–2016, 5 sera collected from patients and tested with PCR, PRNT and ELISA were ONNV+ (O | Haemorrhagic fever, 2016).

4.2.9. Tanzania

1) Outbreak

A ONNV outbreak involving both eastern and western Africa (Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon, Central African Republic, Democratic Republic of the Congo) in 1959–1962 accounted for more than 2 million cases in eastern Africa alone (Rezza et al., 2017; Woodruff et al., 1978). *A. funestus* was identified as the main vector (Lhuillier et al., 1988; Posey et al., 2005). The first ONNV strain was isolated from Gulu (Uganda) in 1959.

2) Outbreak

A ONNV outbreak was first detected in south-central Uganda and then spread to Kenya and Tanzania in 1996–1997 (Sanders et al., 1999). A case-finding serosurvey conducted in January and February 1997 in affected sites in Uganda estimated infection rates at 45–68%. Cross-reactivity with antibodies against CHIKV was observed.

4.2.10. Uganda

1) Outbreak

A ONNV outbreak involving both eastern and western Africa (Uganda, Kenya, Mozambique, Senegal, Malawi, Tanzania, Cameroon, Central African Republic, Democratic Republic of the Congo) in 1959–1962 accounted for more than 2 million cases in eastern Africa alone (Rezza et al., 2017; Woodruff et al., 1978). *A. funestus* was identified as the main vector (Lhuillier et al., 1988; Posey et al., 2005). The first ONNV strain was isolated from Gulu (Uganda) in 1959.

2) Outbreak

A ONNV outbreak was first detected in south-central Uganda and then spread to Kenya and Tanzania in 1996–1997 (Sanders et al., 1999). A case-finding serosurvey conducted in January and February 1997 in affected sites in Uganda estimated infection rates at 45–68%. Cross-reactivity with antibodies against CHIKV was observed. ONNV distribution is presented in Fig. 1.

---

**Fig. 2.** Phylogenetic analysis of 9 ONNV strains (including Igbo Ora, considered an ONNV strain) present in GenBank. Neighbor-joining phylogeny tree was generated using p-distance model with 1000 bootstrap replication. 1044 sites were included from partial E2-E1 sequences. Tip labels indicate GenBank accession number, strain name, country and year of isolation. For NC_001512, sampling country and year are not available.
5. Discussion

In this paper, we report cases of ONNV infections in humans; however, the assessment of ONNV circulation in Africa remains a difficult task for several reasons.

First, the absence of surveillance in most African countries led to fragmentary data including mainly isolated case reports of local people or returning travelers, and sporadic outbreaks. Returning travelers can serve as sentinels, providing information on recent circulation of an infectious pathogen, especially in countries where laboratory diagnosis, especially seroneutralization, is difficult to implement. However, the diagnosis of imported ONNV infections should not only constitute a detection for its own sake, but also provide evidence of viral circulation and transmission in source countries that often do not have the diagnostic capacity to rule in ONNV. Similarly, outbreaks have been reported but not followed by systematic seroprevalence, cross-sectional or follow-up studies; their implementation is necessary in order to evaluate the real scale of ONNV circulation and to identify possible sequence post-infection. This is valid especially for countries that have already experienced large-scale outbreaks (i.e. Kenya, Uganda, Tanzania), and/or where ONNV circulation is suspected to be endemic (LaBeaud et al., 2015).

Second, the scarce seroprevalence data currently available are not robust, due to the cross-reactivity with antibodies raised against closely related alphaviruses. In particular, in several serosurveys described in the article it was hard to discriminate infections caused by ONNV and those caused by CHIKV, since antibodies against the two viruses strongly cross-react if tested by immunofluorescence test (IF), enzyme-linked immunosorbent assay (ELISA), complement fixation test (CF) or haemagglutination inhibition Test (HI) (Woodruff et al., 1978; Olaye et al., 1988; Fokam et al., 2010). Even neutralization tests, normally the gold standard for specificity, are cross-reactive, sometimes in an asymmetric manner (Pezzi et al., 2019). For example, LaBeaud et al. observed that 38% of ONNV- and CHIKV-positive samples had high titers for both alphaviruses using PRNT, and were then classified as “equivocal” (LaBeaud et al., 2015). The presence of antibodies against ONNV and CHIKV may sometimes be the result of infection by both viruses (which would imply that infection by one pathogen does not provide protection against the other), or may be due to massive cross-reactivity because of the antigenic similarity between the two viruses. However, strong cross-protection has been reported in studies of CHIKV vaccines, suggesting that most cross-reactivity results from single infections (Partidos et al., 2012). Since ONNV and CHIKV are phylogenetically close, some degree of cross-protection is highly probable; dual reactivity against both ONNV and CHIKV is likely to reflect the limited discriminatory capacity of available neutralization assays. Another explanation could be the circulation of a novel third virus that induces antibodies that cross-neutralize both CHIKV and ONNV.

Third, the scarcity of available ONNV genetic data limits molecular epidemiology studies and makes difficult to map viral spread throughout Africa. According to the 9th report of the International Committee on Taxonomy of Viruses (ICTV) (Genus, 2019), ONNV forms with CHIKV a monophyletic group within the Semliki Forest complex. Phylogenetic analysis with partial genome sequences available from GenBank shows that ONNV isolates constitute a distinct evolutionary branch apart from all CHIKV strains, with two major clades among ONNV strains (Fig. 2) (Powers et al., 2000). The relationship among viral strains does not depend on sample year and/or location, suggesting frequent movement of ONNV through the African continent. Igbo Ora virus, first isolated in 1966 from Nigerian patients and sometimes considered as a separate virus, is closely related to an ONNV strain isolated during 1996–97 outbreak in Uganda, supporting the idea that it should be considered a member of species ONNV (Genus, 2019; Lanciotti et al., 1998).

The analysis of the distribution of ONNV cases in time and space suggests a certain periodicity of outbreaks and geographical limitations in viral spread. ONNV has been capable of causing two known large-scale epidemics, one in 1959–1962 and the following one in 1996–1997. As concerns geographical distribution of ONNV cases, Fig. 1 shows a restriction to sub-Saharan countries in both East and West Africa. Since ONNV is transmitted by malaria vector mosquitoes (Anopheles species), it is not surprising that our ONNV map and those reporting Anopheles and malaria cases distribution are overlapping (Annual Report | About | P, 2019; Guerra et al., 2008). The relationship between ONNV and malaria transmission remains to be investigated. An unusual drop in malaria transmission was noted at the same time as intense circulation of ONNV in southern Uganda during the 1959–1962 epidemic, in a period of the year with favorable meteorological conditions for high mosquito densities (de Zulueta et al., 1962). This observation raises interesting questions regarding the growth and transmission of malaria parasites (Plasmodium falciparum) in the anopheles mosquitoes infected by ONNV.

Investigating the relationship between ONNV and co-circulating pathogens (primarily CHIKV), as well as factors that limit ONNV distribution at regular intervals to some sub-Saharan countries other than the diffusion of competent vectors (i.e. the presence of natural reservoirs) would most probably improve our understanding of ONNV epidemiology.

According to available data on ONNV distribution, experts identified several gaps of knowledge and provided adapted recommendations (Paragraphs 6.1 to 7. The aim was to identify and suggest research priorities in the field.

6. Gaps of knowledge

6.1. Disease surveillance and epidemiology

Despite ONNV detection in humans, vertebrates and mosquitoes throughout African continent, the surveillance strategy remains unsatisfactory. In some African countries, evidence for ONNV circulation relies on small identified outbreaks (South Sudan, Côte d’Ivoire) or single case reports (Chad, Ghana); in others, few seroprevalence studies have been performed (Nigeria, Kenya) but the robustness of data is disputable. Altogether, the scarcity of currently available information does not allow to provide a clear picture of the actual scale of virus spread.

6.2. Entomological and environmental surveillance

Despite the epidemiologic studies described above, fundamental information on ONNV maintenance, presumably through an enzootic cycle, remains wanting. This information includes both enzootic reservoir or amplification hosts, enzootic vectors, and mechanisms of human-mosquito-human epidemic emergence.

6.3. Laboratory tests for seroprevalence studies

The close phylogenetic relationship between ONNV and CHIKV explains why anti-ONNV and anti-CHIKV antibodies can barely be distinguished. This is very difficult –if not impossible-using standard ELISA or immunofluorescence test (Pezzi et al., 2019), but even seroneutralization tests often generate equivocal results. Accordingly, the choice of the best laboratory test to use in seroprevalence studies is crucial, but it is doubtful that adapted and convenient serological tools and interpretation algorithms are currently available to expedite accurate (and large scale) seroepidemiological studies.

6.4. Diagnosis of acute cases

Very few incident cases are reported, most probably because diagnostic tests that should be used at the acute phase of the disease are rarely available. IgM serological assays have not been evaluated, most
probably poorly discriminate with CHIKV, and commercial kits do not exist. Very few molecular assays for ONNV detection exist, and their performances (in terms of specificity and sensitivity) have never been evaluated through comparative studies. In practice they are rarely available and used (Pezzi et al., 2019). Information about kinetics of viral load are scarce and concern just sera samples; other body fluids have never been tested. No International Standards (IS) are currently available and External Quality Assessment (EQAs) have never been organized to evaluate laboratories capacity to diagnose ONNV infection.

6.5. Cross-protection

It is unknown whether individuals infected by ONNV or CHIKV can secondarily be infected by the other virus. It is presumed, due to the close antigenic relationship, that the infection by one virus protects against subsequent infection by the other, but since the seroneutralizing relationship is not symmetric (antibodies to CHIKV provide better protection against ONNV than the opposite), this remains to be confirmed. In addition, serological patterns associated with sequential exposure to the two viruses are not characterized.

6.6. Natural history

The natural history of the disease deserves to be better investigated, including acute manifestations and long-term sequelae. Moreover, whereas a variety of long-term (mostly rheumatologic) complications of the disease have been observed for the related chikungunya virus since the Indian Ocean outbreak (constituting an actual “post-CHIKV” syndrome), longitudinal studies of ONNV infections have not been performed to determine whether a “post-ONNV” syndrome exists.

7. Expert recommendations

7.1. Disease surveillance and epidemiology

Specific efforts are required for improving our knowledge about ONNV circulation and epidemiology at a large scale (including clinical epidemiology). ONNV should be more frequently included in molecular diagnostic panels for febrile illnesses of unknown origin in Africa, and seroprevalence studies should be performed. This obviously requires improved diagnostic assays and access.

7.2. Entomological and environmental surveillance

Entomology studies (including investigation of possible vector switches) and characterization of the natural enzootic cycle in reservoirs and vectors should be promoted.

7.3. Laboratory tests for seroprevalence studies

Accurate assays and algorithms allowing to detect IgG antibodies to ONNV and to distinguish them from IgG to CHIKV are needed. At this stage, performing seroneutralization confirmation is mandatory after performing a screening assay (e.g. ELISA, HI or IF assays) and allows asserting ONNV circulation when titers against ONNV are clearly higher than those against CHIKV. However, a proportion of samples remains without clear identification, in particular in case of co-circulation of both viruses (LaBeaud et al., 2015). Clear interpretation guidelines or new specific assays are required and reference serological standards are needed (possibly produced from non-human primates (Pezzi et al., 2019)).

7.4. Diagnosis of acute cases

For diagnosis at the acute stage of the disease, viral co-circulation requires the development of molecular and serological multiplex tools to differentiate ONNV from CHIKV in Africa. Identification and analysis of acute cases is mandatory to better know the natural history of the disease and identify severe and complicated forms. Viremia kinetics and viral loads in different body fluids should be better documented, as well as the kinetics of immune response. International Standards (IS) should be made available, both molecular and serological. Moreover, External Quality Assessments (EQAs) should be organized in order to assess laboratory capacity of detecting ONNV with both molecular and serological tools.

7.5. Cross-protection

Cross-protection studies between ONNV and related alphaviruses, in particular CHIKV, should be implemented. This could be done using samples from both naturally exposed humans and experimentally infected non-human primates.

7.6. Natural history

Studies should be performed in order to better characterize the natural history of ONNV disease and to identify long term sequelae post infection.

Acknowledgement

Publication fees were covered by the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.antiviral.2019.104611.

References


o’nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine 30, 4638–4643.


